Figure - available from: Pediatric Cardiology
This content is subject to copyright. Terms and conditions apply.
Medication use in children and young adults with Marfan syndrome following the PHN trial publication in 2014. The longer segment of line indicates progression of prescription prevalence during the pre-publication period. The vertical gap between the beginning of 2014 and end of 2014 indicates the immediate effect. The shorter line represents the progression of prescription prevalence in the post-publication period. BB beta-blocker, ARB angiotensin receptor blocker, ACEI angiotensin converting enzyme inhibitor
Source publication
The Pediatric Heart Network (PHN) trial showed similar efficacy of β-blockers (BB) and angiotensin receptor blockers (ARB) for aortic root dilation in Marfan syndrome, but the impact on prescription practices is unknown. We hypothesized BB and ARB prescriptions would increase after the trial results were published (2014). Prescription data (2007–20...
